You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

March 9, 2012

Food Registration with the Thai FDA: Overcoming Pitfalls

Bangkok Post, Corporate Counsellor Column

With its diverse range of consumers seeking both traditional wares and more modern Western-influenced products, Thailand, like Vietnam and many other Asean countries, has become a hugely attractive and a lucrative market for foreign and local food manufacturers alike.

But for foreign companies that want to import products into Thailand, their first interaction with the Thai Food and Drug Administration (FDA) too often ends with a firm rebuttal, as their products are rejected for registration or they face significant delays. This is especially true if the food and drug regulators in the countries they are used to dealing with lack a strong pre-marketing review system but instead rely only on a post-marketing process to protect consumers in the event of product liability lawsuits, such as the US.

Although these FDA obstacles can be frustrating, companies can achieve success by familiarizing themselves with Thai FDA practices and preparing for potential pitfalls.

New Food Ingredients

Prior to starting the registration process for a food product, a company must first determine whether all its ingredients have already been approved by the Thai FDA. An ingredient that is commonly registered in another country may not necessarily have been registered with the FDA.

For new ingredients, the FDA will request additional supporting documents. For example, a product used in food consumption must be able to show a history of use for more than 15 years in a foreign country and/or safety data.

Companies need to make strategic decisions about whether to retain the new food ingredient in a formula. On the one hand, the new ingredient can be helpful in differentiating the product from competitors, but on the other hand companies face an extended registration process when new ingredients are included.

Misclassification of Food

Companies often have a misconception that if their products are classified and registered in a certain category in a country such as Singapore, then they would fall into the same category in Thailand. This is not necessarily the case. Prior to FDA submission, an applicant must be fully aware of: (1) the ingredient list for its products; (2) the source of the ingredients; (3) the manufacturing process; (4) the objectives of use; and (5) the targeted consumer group. These factors will allow the company to:

  • Preliminarily classify the product; and
  • Assist in answering registration questions from the Thai FDA.

Misclassifying the product will delay the registration process, because companies are not permitted to transfer a dossier from one category to another. If a category change needs to be made, then the company must restart the application.

Requirements differ from one category to another. For example, if you misclassify a dietary supplement in the food supplement category, which does not require any analysis, when it is in fact a beverage in a sealed container, then this would mean additional documents and a detailed analysis are required. This causes further delays.

These delays can be avoided by carefully preparing and reviewing product ingredients and information before considering the classification.

Preparing Your Dossier Carefully

Asean lacks a system for harmonization of food products, and thus the product dossier requirements differ between member countries. In addition, some other countries, including the US, do not necessarily issue the same types of documents required by the Thai FDA.

The Thai FDA conducts a careful substantive examination of the documents provided, and any discrepancies will further delay the registration process. Companies should ensure that all documents, as requested by the FDA, are complete and consistent. If some documents are unavailable, then be prepared to provide a suitable response to the FDA.

Health Claims on Labels

The Thai FDA takes a stricter approach to claims on labels than in other countries, including the US. For example, the Thai FDA permits nutrition claims if appropriate analysis is conducted. However, health claims—that is, claims relating to benefits, efficacies and functions of the product—are forbidden.

Foreign companies perceive the Thai FDA interpretation as very strict, as it requires a complete amendment of their labels when they are designed abroad. In some cases, however, it is worth negotiating with the FDA, as its officials are willing to learn from industry specialists. It is important for industries to work closely with the FDA in providing assistance on how to differentiate between health claims, slogans and other advertising statements.

Regional Market

Food manufacturers and importers should no longer view Thailand as a stand-alone market when targeting it for their products, but rather part of the overall Asean Economic Community that is due to take effect in 2015. Using this approach, companies can maximize efficiency by planning to register their products across several Asean countries.

Understanding the mechanisms adopted by local Asean FDAs may appear cumbersome, but with assistance from technical experts any company can enjoy a smooth product launch and reap the considerable benefits offered by the increased integration of Asean markets.

RELATED INSIGHTS​ 

October 15, 2025
The Indonesian Food and Drug Administration (BPOM) has introduced more stringent oversight of health supplements containing probiotics with new guidelines that require clinical trials for certain products and expanded documentation standards. BPOM Regulation No. 17 of 2025 replaces the previous 2021 regulation and establishes a comprehensive framework for evaluating probiotic strains used in health supplements. Assessment Requirements The new regulation expands the scope of assessment to include not only categorization and documentation but also technical procedures, strain classification, and clinical trial requirements. Unlike the previous regulation, which provided general guidance, the updated framework creates a comprehensive system for evaluating both registered probiotic strains and new or combined strains. Manufacturers must now submit supporting documentation covering strain identification and functional characterization, safety, efficacy, and product quality. The previous regulation required documentation only on safety, efficacy, and quality. Clinical Trials One of the most significant changes is the requirement for clinical trials conducted in Indonesia for applications that include benefit claims other than maintaining digestive health, or where there are modifications to benefit claims. The regulation specifies that phase 1 trials must demonstrate safety, while phase 2 trials must validate efficacy using statistically valid methods such as double-blind, randomized, placebo-controlled studies). In addition, phase 3 and phase 4 trials may be required, and postmarket surveillance data must be submitted. Technical Assessment Framework Annex 4, a newly introduced section, establishes technical procedures for assessing health supplements containing probiotics in Indonesia. This comprehensive framework outlines criteria for evaluating new probiotic strains, including strain identification, functional characterization, safety, efficacy, and product quality. The annex introduces a clear classification of claims for health supplement products containing probiotics: General claims(e.g., maintaining digestive health). Functional claims(e.g., normal biological function or activity in the body). Risk reduction claims(e.g., lowering disease risk). The regulation restricts use of the term
October 3, 2025
On September 26, 2025, the Contract Committee under Thailand’s Consumer Protection Board issued a regulation that aims to standardize contracts and enhance consumer protection within the beauty and wellness industry. The Notification on Prescribing the Beauty Service Business as a Contract-Controlled Business B.E. 2568 (2025), which takes effect on January 24, 2026, requires business operators to use a prescribed standard contract in Thai and adhere to strict mandatory provisions and prohibitions. These regulations apply to operators across all in-person and online service channels, including via digital platforms. “Beauty services business” is defined as the provision of services under an agreement allowing consumers to receive a series of treatments, either over a set number of sessions or within a set period. This includes massage, spa, other methods for cleanliness, beauty, or care of facial or body skin, and weight control and body shaping—including services offered electronically. The law excludes surgery, liposuction, and medical treatments performed by licensed practitioners. The notification establishes the following key requirements: Mandatory contract and formatting. All contracts with consumers must use the standard contract form, in Thai, with clear, readable text (minimum font size of 2 millimeters, no more than 11 characters per inch), and include all essential terms from the annexed form. Contract execution. Contracts must be made in duplicate, with one copy given to the consumer at signing. For agreements concluded through electronic channels, the process must comply with the Electronic Transactions Act and use the same required terms. Digital platforms. Business operators who provide services facilitated through a digital platform as an intermediary are ultimately responsible for ensuring the consumer receives a compliant contract. Prohibited clauses. The law prohibits clauses that limit or exclude liability for damages to life, body, health, mind, or property resulting from breach of contract or a wrongful act;
September 16, 2025
Since Thailand formally removed Mitragyna speciosa (kratom) from the list of narcotic drugs, the country has progressed from outright prohibition to a structured, license-based regime. While the Ministry of Public Health oversees cannabis plant regulation, the Ministry of Justice (MOJ) is the regulatory authority overseeing kratom plants. For the avoidance of doubt, separate Ministry of Public Health notifications prohibit the use of kratom as a food ingredient unless a food safety evaluation has been conducted; however, this restriction does not affect trade in unprocessed leaves per se. For businesses in Thailand dealing exclusively in kratom leaves, the most consequential development is the Ministerial Regulation on the Application for Permits and Notifications for the Importation and Exportation of Kratom Leaves B.E. 2568 (2025), a bylaw of the Kratom Plant Act 2022. The ministerial regulation establishes the following notable definitions: “Kratom leaves”: Fresh or dried leaves in their natural, unprocessed state (no extracts, concentrates, or infused products). “Import/Export”: Any act of bringing kratom leaves into or out of Thailand, whether for commercial sale, industrial processing abroad, or research. Import/Export Licensing Under the Kratom Plant Act, a license is mandatory for importing or exporting kratom leaves. Individuals, juristic persons, community enterprises, and state agencies in Thailand are eligible to obtain a license to import (or a license to export) kratom leaves. Licenses are available to qualified individuals and juristic persons. Individuals must satisfy the following qualifications to be eligible for a license: Thai nationality, ≥ 20 years old, resident in Thailand. Not incompetent, quasi-incompetent, or under legal guardianship. No license suspension currently in force under the Kratom Act or Narcotics Code. No license revocation in the previous two years. No conviction under the Kratom Act or Narcotics Code within the previous two years (unless fully released from punishment). Juristic persons must satisfy
September 4, 2025
With advancements in health technology, telemedicine has taken on a wider online presence in Thailand. Under the Medical Facility Act, licensed clinics and hospitals may now diagnose, prescribe, and issue electronic prescriptions during a video call, provided they maintain patient confidentiality and proper recordkeeping. As a complementary concept, a telepharmacy allows a pharmacist to verify prescriptions, counsel patients, and dispense medication from a remote site. Hospitals, clinic chains, and some retail pharmacy groups have adopted “drive-thru” or “locker” pick-up points where drugs are bagged only after a real-time video consultation with a registered pharmacist. The clear benefits of telehealth include shorter waiting times and broader access to specialists, which is in the public interest. Drug Distribution and Advertising in Thailand The online pharmacy ecosystem creates a legal bridge in that once a teleconsulting doctor issues an e-prescription, a licensed pharmacy can lawfully dispense and deliver the medicine prescribed to the patient’s door. Nonetheless, the critical compliance component remains the advertising of medicinal drugs. It is still not allowed to advertise prescription/pharmacy-dispensed drugs to the public in Thailand. Although Thailand’s Drug Act of 1967 was written more than half a century ago, it still governs the trading of every medicinal drug that makes its way to consumers in Thailand—whether bought at a pharmacy or delivered with a few taps on a smartphone. First and foremost, the pharmacy must hold a license to sell medicinal drugs as a retailer. It is also mandatory that arrangements be made for a pharmacist to be on duty during opening hours. Drugs are classified into three main categories: prescription drugs, pharmacy-dispensed drugs, and over-the-counter (OTC) drugs. The listing of OTC drugs with their prices via an online platform is allowed, as only OTC drugs may be advertised directly to the public. However, naming or showing